Polina Prusevich

Title: Polina Prusevich: Innovator in Cancer and Neurodegenerative Disease Research

Introduction

Polina Prusevich is a prominent inventor based in Baltimore, MD (US). She has made significant contributions to the field of biomedical research, particularly in the development of novel therapeutic agents targeting critical enzymes involved in cancer and neurodegenerative diseases.

Latest Patents

Polina Prusevich holds a patent for "Inhibitors of histone lysine specific demethylase (LSD1) and histone deacetylases (HDACs)." This patent describes a series of phenelzine analogs that comprise a phenelzine scaffold linked to an aromatic moiety. These compounds serve as inhibitors of lysine-specific demethylase 1 (LSD1) and/or one or more histone deacetylases (HDACs). The disclosed phenelzine analogs exhibit potency and selectivity for LSD1 versus MAO and LSD2 enzymes. They also demonstrate significant changes in bulk and gene-specific histone methylation, anti-proliferative activity in various cancer cell lines, and neuroprotection in response to oxidative stress. Consequently, these phenelzine analogs can be utilized to treat diseases, conditions, or disorders related to LSD1 and/or HDACs, including cancers and neurodegenerative diseases. She has 1 patent to her name.

Career Highlights

Polina Prusevich is affiliated with Johns Hopkins University, where she conducts her research. Her work has garnered attention for its potential impact on therapeutic strategies for complex diseases.

Collaborations

Polina has collaborated with notable researchers in her field, including Philip A. Cole and Shonoi Ming. These collaborations have further enhanced the scope and depth of her research endeavors.

Conclusion

Polina Prusevich is a trailblazer in the field of biomedical research, with a focus on developing innovative treatments for cancer and neurodegenerative diseases. Her contributions through her patent and collaborations highlight her commitment to advancing medical science.